Silo Pharma, Inc.
For the period ended Oct 24, 2025. Filed Sep 5, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Oct 24, 2025 · Filed Sep 5, 2025
SILO$1.33+3.1%Stored close · as of Nov 6, 2026
Contents
Pay Versus Performance Table
| Year (1) | Summary Compensation Table Total for PEO | Compensation Actually Paid to PEO (2) | Average Summary Compensation Table Total for Non-PEO NEOs | Average Compensation Actually Paid to Non-PEO NEOs (2) | Value of Initial Fixed $100 Investment Based On Total Shareholder Return | Net Income (Loss) |
|---|---|---|---|---|---|---|
| 2024 | $630,051 | $630,051 | $88,600 | $88,600 | 6.19 | $(4,392,880) |
| 2023 | $569,009 | $569,009 | $62,692 | $62,692 | 6.79 | $(3,700,683) |
| 2022 | $352,500 | $352,500 | $15,000 | $15,000 | 15.83 | $(3,908,551) |
| (1) | The PEO (CEO) in the 2024, 2023 and 2022 reporting year is Eric Weisblum. The non-PEO NEOs in the 2024, 2023 and 2022 reporting year is Dan Ryweck. |
| (2) | The CAP was calculated beginning with the PEO’s SCT total. No amounts were deducted from or added to the applicable SCT total compensation. Since all equity awards were fully vested prior to 2021, no reconciliation to with respect to equity awards for summary compensation numbers was required. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.